A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
Clinical trial NCT05397119 · COMPLETED
Trial details
- NCT number
- NCT05397119
- Sponsor
- BlueWillow Biologics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-07
- Primary completion
- 2023-10-12
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.